This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 7:e30275
Callhoff J, Sieper J, Weiss A, Zink A, Listing J (2015) Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74:1241–1248
Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68:1136–1145
Rubbert-Roth A (2012) Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 51(Suppl 5):v38–47
British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60:800–805
Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772
Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G et al (2015) Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 74:1848–1853
Son CN, Jun JB, Kim JH, Sung IH, Yoo DH, Kim TH (2014) Follow-up testing of interferon-gamma release assays are useful in ankylosing spondylitis patients receiving anti-tumor necrosis factor alpha for latent tuberculosis infection. J Korean Med Sci 29:1090–1093
Scrivo R, Sauzullo I, Mengoni F, Iaiani G, Vestri AR, Priori R et al (2012) Serial interferon-gamma release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clin Rheumatol 31:1567–1575
Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL (2012) Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assay. Ann Rheum Dis 71:231–237
Kim KH, Lee SW, Chung WT, Kim BG, Woo KS, Han JY et al (2011) Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 31:271–278
Cuomo G, D'Abrosca V, Iacono D, Pantano I (2017) The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. Clin Rheumatol 36:457–461
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625–639
Favalli EG, Caporali R, Sinigaglia L, Pipitone N, Miniati I, Montecucco C et al (2011) Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clin Exp Rheumatol 29:S15–27
Cantini F, Niccoli L, Goletti D (2014) Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 91:56–64
Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ (2014) Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53:1872–1885
Jambaldorj E, Han M, Jeong JC, Koo TY, Min SI, Song EY et al (2017) Poor predictability of QuantiFERON-TB assay in recipients and donors for tuberculosis development after kidney transplantation in an intermediate-TB-burden country. BMC Nephrol 18:88
Chung W, Lee K, Jung Y, Kim Y, Park J, Sheen S et al (2015) Serum CXCR3 ligands as biomarkers for the diagnosis and treatment monitoring of tuberculosis. Int J Tuberc Lung Dis 19:1476–1484
World Health Organization (2019) Global health observatory data repository. Incidence Data by country. https://apps.who.int/gho/data/view.main.57040ALL?lang=en. Accessed 21 Oct 2019
Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K (2010) Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep 59:1–25
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588
van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368
Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34:12–18
Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522–528
Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K et al (2004) Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 170:59–64
Scrivo R, Sauzullo I, Mengoni F, Priori R, Coppola M, Iaiani G et al (2013) Mycobacterial interferon-gamma release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol 40:157–165
Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13:R141
Mariette X, Gottenberg JE, Ravaud P, Combe B (2011) Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 50:222–229
Lahiri M, Dixon WG (2015) Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol 29:290–305
Calarota SA, Aberle JH, Puchhammer-Stockl E, Baldanti F (2015) Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications. J Clin Virol 70:109–119
Fernandez-Ruiz M, Kumar D, Humar A (2014) Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunol 3:e12
Caston JJ, Cantisan S, Gonzalez-Gasca F, Paez-Vega A, Abdel-Hadi H, Illescas S et al (2016) Interferon-gamma production by CMV-specific CD8+ T lymphocytes provides protection against cytomegalovirus reactivation in critically ill patients. Intensive Care Med 42:46–53
Tarasewicz A, Debska-Slizien A, Rutkowski B (2016) Clinical utility of QuantiFERON-cytomegalovirus test in management of kidney transplant recipients. Transplant Proc 48:1650–1653
Cliff JM, Kaufmann SH, McShane H, van Helden P, O'Garra A (2015) The human immune response to tuberculosis and its treatment: a view from the blood. Immunol Rev 264:88–102
This study was supported by a grant of the Korean Health Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI14C1774). We thank Hye Sun Lee, Ph.D. and Sinae Kim, M.S., Biostatistics Collaboration Unit, Yonsei University College of Medicine, for statistical consultation. We also thank Editage (https://www.editage.co.kr) for English editing.
Conflict of interest
The authors declare that there are no conflicts of interest in relation to this article.
All procedures were performed in accordance with the ethical standards of the Institutional Review Board of Gangnam Severance Hospital (IRB No: 3-2016-0240) and with the 1964 Helsinki declaration. The approval date of IRB was October 17, 2016.
Related congress abstract publication
Preliminary data of this study was presented in the poster presentation session of EULAR Congress 2017 that was held in Madrid, Spain; Min-Chan Park, Hye Won Kim, Sang Hoon Han (2017) Positive conversion of tuberculosis screening results and incidence of active tuberculosis infection in patients receiving biologic treatment. Ann Rheum Dis 76 Suppl 2:762. https://doi.org/10.1136/annrheumdis-2017-eular.1286; presentation number, FRI0717; and presentation date, June 16, 2017.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kim, H.W., Kwon, O.C., Han, S.H. et al. Positive conversion of interferon-γ release assay in patients with rheumatic diseases treated with biologics. Rheumatol Int 40, 471–479 (2020). https://doi.org/10.1007/s00296-019-04510-6
- Interferon-γ release assay
- Rheumatoid arthritis
- Ankylosing spondylitis